Following the continued success of New Horizons in Cardiomyopathy (NHC) in 2025, Radcliffe Cardiology is delighted to return with the next edition on Tuesday 26 and Wednesday 27 May 2026.
The event will offer an engaging and interactive platform for healthcare professionals to stay up to date on the diagnosis and management of cardiac amyloidosis and cardiomyopathy.
Across the two days, the programme will feature expert-led sessions covering key developments in cardiomyopathy and cardiac amyloidosis. Attendees can expect in-depth discussions on disease mechanisms, current best practices, diagnostic strategies, real-world case discussions and the latest therapeutic innovations, all designed to support clinical decision-making and improve patient outcomes.
The course directors, Dr Rodney Falk (Brigham and Women's Hospital, Boston, US), Dr Margot Davis (Vancouver General Hospital, Vancouver, CA) and Prof Iacopo Olivotto (Careggi University Hospital, Florence, IT) will lead the event and bring together a distinguished group of faculty members who are renowned experts. Their combined knowledge will provide attendees with a well-rounded, collaborative learning experience.
Register now to stay at the forefront of innovation in cardiomyopathy and cardiac amyloidosis. We look forward to welcoming you to New Horizons in Cardiomyopathy 2026.
*New Horizons in Cardiomyopathy 2026's programme will be submitted to the European Board for Accreditation of Continuing Education for Health Professionals (EBAC).
Margot Davis
Course Director
University of British Columbia, Vancouver, CA
more info
Rodney Falk
Course Director
Brigham and Women's Hospital, Boston, US
more info
Iacopo Olivotto
Course Director
Careggi University Hospital, Florence, IT
more info
-
Increase the awareness of at-risk patients
-
Improve understanding of screening procedures
-
Provide guidance on the use of imaging for diagnosis
-
Improve awareness on current and emerging treatment
-
Provide guidance on initiating treatment and managing comorbidities
If you're interested in becoming a partner at NHC, please contact sales@radcliffe-group.com
Official Journal
Cardiac Failure Review (CFR) is an international, English language, peer-reviewed journal that publishes articles continually to CFRjournal.com and aims to assist time-pressured physicians to stay abreast of key advances and opinion in the area of heart failure.
The journal comprises balanced and comprehensive review articles and original research written by leading authorities. The journal provides updates on a range of salient issues to support physicians in developing their knowledge and effectiveness in day-to-day clinical practice.
The journal endeavours to support the continuous medical education of specialist and general cardiologists and disseminate knowledge of the field to the wider cardiovascular community.
Partnership: CFR is the official journal of the Italian Heart Failure Association (ITAHFA).
Journal website: www.cfrjournal.com
About Radcliffe Cardiology
We are Radcliffe, a knowledge network for the cardiovascular community We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively. We bring medical knowledge to life From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare. Our work is underpinned by 3 core principles:
-
We build on the best science
-
We work hands-on with our community
-
We bring fresh thinking
Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients. For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com


